Ajax loader

Topic 

Topic 

Composition 

Composition 

Orientation 

Orientation 

Can't find what you're looking for?

 

Be sure to Sign in to see all available content.

 

If you don't have an account, Register here.

Search results for: Schering-Plough

Business
Business 
Merck Buys Schering-Plough For $41 Billion - 10 Mar 2009 
16 PICTURES 
MARKETS-JAPAN-STOCKS/
RTXCKHL 
March 10, 2009 
People look at a display showing stock prices in downtown Tokyo March 10, 2009. Japan's Nikkei average... 
Tokyo, Japan 
People look at a display showing stock prices in downtown Tokyo 
People look at a display showing stock prices in downtown Tokyo March 10, 2009. Japan's Nikkei average fell 0.7 percent on Tuesday as drugmakers such as Astellas Pharma slid among worries about their global competitiveness after Merck proposed to take over Schering-Plough. REUTERS/Michael Caronna (JAPAN BUSINESS) 
MARKETS-JAPAN-STOCKS/
RTXCKHK 
March 10, 2009 
People crossing the street are reflected in a display showing stock prices in downtown Tokyo March 10,... 
Tokyo, Japan 
People crossing the street are reflected in a display showing stock prices in downtown Tokyo 
People crossing the street are reflected in a display showing stock prices in downtown Tokyo March 10, 2009. Japan's Nikkei average fell 0.7 percent on Tuesday as drugmakers such as Astellas Pharma slid among worries about their global competitiveness after Merck proposed to take over Schering-Plough. REUTERS/Michael Caronna (JAPAN BUSINESS IMAGE OF THE DAY TOP PICTURE) 
SCHERINGPLOUGH-MERCK/
RTXCK41 
March 09, 2009 
A view of the Schering-Plough campus in Kenilworth, New Jersey March 9, 2009, after Merck & Co Inc said... 
Kenilworth, UNITED STATES 
A view of the Schering-Plough campus in Kenilworth 
A view of the Schering-Plough campus in Kenilworth, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines. REUTERS/Jeff Zelevansky (UNITED STATES BUSINESS HEALTH) 
SCHERINGPLOUGH-MERCK/
RTXCK3Y 
March 09, 2009 
A view of the Schering-Plough campus in Kenilworth, New Jersey March 9, 2009, after Merck & Co Inc said... 
Kenilworth, UNITED STATES 
A view of the Schering-Plough campus in Kenilworth, New Jersey March 9, 2009 
A view of the Schering-Plough campus in Kenilworth, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines. ÊREUTERS/Jeff Zelevansky (UNITED STATES BUSINESS HEALTH) 
SCHERINGPLOUGH-MERCK/
RTXCK2X 
March 09, 2009 
A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would... 
Linden, UNITED STATES 
A view of the Merck & Co. campus in Linden, New Jersey 
A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines. REUTERS/Jeff Zelevansky (UNITED STATES BUSINESS HEALTH) 
SCHERINGPLOUGH-MERCK/
RTXCK2R 
March 09, 2009 
A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would... 
Linden, UNITED STATES 
A view of the Merck & Co. campus in Linden, New Jersey 
A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines. ÊREUTERS/Jeff Zelevansky (UNITED STATES BUSINESS HEALTH) 
SCHERINGPLOUGH-MERCK/
RTXCK2M 
March 09, 2009 
A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would... 
Linden, UNITED STATES 
A view of the Merck & Co. campus in Linden, New Jersey 
A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines. REUTERS/Jeff Zelevansky (UNITED STATES BUSINESS HEALTH) 
SCHERINGPLOUGH-MERCK/
RTXCK2I 
March 09, 2009 
A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would... 
Linden, UNITED STATES 
A view of the Merck & Co. campus in Linden, New Jersey 
A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines. REUTERS/Jeff Zelevansky (UNITED STATES BUSINESS HEALTH) 
SCHERINGPLOUGH-MERCK/
RTXCK23 
March 09, 2009 
A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would... 
Linden, UNITED STATES 
A view of the Merck & Co. campus in Linden, New Jersey 
A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines. REUTERS/Jeff Zelevansky (UNITED STATES BUSINESS HEALTH IMAGE OF THE DAY TOP PICTURE) 
SCHERINGPLOUGH-MERCK/
RTXCK1V 
March 09, 2009 
A view of the Schering-Plough campus in Kenilworth, New Jersey March 9, 2009, after Merck & Co Inc said... 
Kenilworth, UNITED STATES 
A view of the Schering-Plough campus in Kenilworth 
A view of the Schering-Plough campus in Kenilworth, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines. REUTERS/Jeff Zelevansky (UNITED STATES BUSINESS HEALTH IMAGE OF THE DAY TOP PICTURE) 
SCHERINGPLOUGH MERCK/
RTXCJUL 
March 09, 2009 
A sample of the drug Singulair made by Merck & Co. Inc. is seen in New York March 9, 2009. Merck & Co... 
New York, UNITED STATES 
A sample of the drug Singulair 
A sample of the drug Singulair made by Merck & Co. Inc. is seen in New York March 9, 2009. Merck & Co Inc announced it would acquire Schering-Plough Corp for $41 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks. REUTERS/Chip East (UNITED STATES HEALTH BUSINESS) 
SCHERINGPLOUGH MERCK/
RTXCJUJ 
March 09, 2009 
A sample of the drug Singulair made by Merck & Co. Inc. is seen in New York March 9, 2009. Merck & Co... 
New York, UNITED STATES 
A sample of the drug Singulair 
A sample of the drug Singulair made by Merck & Co. Inc. is seen in New York March 9, 2009. Merck & Co Inc announced it would acquire Schering-Plough Corp for $41 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks. REUTERS/Chip East (UNITED STATES HEALTH BUSINESS) 
SCHERINGPLOUGH MERCK/
RTXCJUH 
March 09, 2009 
A sample of the drug Nasonex made by the Schering Corporation is seen in New York, March 9, 2009. Merck... 
New York, UNITED STATES 
A sample of the drug Nasonex 
A sample of the drug Nasonex made by the Schering Corporation is seen in New York, March 9, 2009. Merck & Co Inc announced it would acquire Schering-Plough Corp for $41 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks. REUTERS/Chip East (UNITED STATES HEALTH) 
SCHERINGPLOUGH MERCK/
RTXCJUF 
March 09, 2009 
A sample of the drug Proventil made by Schering Corporation is seen in New York March 9, 2009. Merck... 
New York, UNITED STATES 
A sample of the drug Proventil 
A sample of the drug Proventil made by Schering Corporation is seen in New York March 9, 2009. Merck & Co Inc announced it would acquire Schering-Plough Corp for $41 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks. REUTERS/Chip East (UNITED STATES HEALTH) 
SCHERINGPLOUGH MERCK/
RTXCJUB 
March 09, 2009 
A sample of the drug Nasonex made by the Schering Corporation is seen in New York March 9, 2009. Merck... 
New York, UNITED STATES 
A sample of the drug Nasonex 
A sample of the drug Nasonex made by the Schering Corporation is seen in New York March 9, 2009. Merck & Co Inc announced it would acquire Schering-Plough Corp for $41 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks. REUTERS/Chip East (UNITED STATES HEALTH BUSINESS) 
SCHERINGPLOUGH MERCK/
RTXCJU5 
March 09, 2009 
A sample of the drug Nasonex, made by the Schering Corporation, is seen in New York, March 9, 2009. ... 
New York, UNITED STATES 
A sample of the drug Nasonex made by the Schering Corporation 
A sample of the drug Nasonex, made by the Schering Corporation, is seen in New York, March 9, 2009. Merck & Co Inc announced it would acquire Schering-Plough Corp for $41 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks. REUTERS/Chip East (UNITED STATES BUSINESS HEALTH) 
SCHERINGPLOUGH-MERCK/
RTXCJPF 
March 09, 2009 
Richard Clark, Chairman and C.E.O. of Merck, speaks at the Reuters Health Summit in New York, in this... 
New York, UNITED STATES 
File photo of Richard Clark, Chairman and C.E.O. of Merck speaking at the Reuters Health Summit in New... 
Richard Clark, Chairman and C.E.O. of Merck, speaks at the Reuters Health Summit in New York, in this file photo taken November 19, 2008. Merck & Co Inc. said on March 9, 2009 that it would acquire Schering-Plough Corp for $41.1 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks. REUTERS/Brendan McDermid/Files (UNITED STATES BUSINESS HEALTH SCI TECH HEADSHOT) 
SCHERINGPLOUGH-MERCK/
RTXCJPA 
March 09, 2009 
Richard Clark, Chairman and C.E.O. of Merck, speaks at the Reuters Health Summit in New York, in this... 
New York, UNITED STATES 
File photo of Richard Clark, Chairman and C.E.O. of Merck speaking at the Reuters Health Summit in New... 
Richard Clark, Chairman and C.E.O. of Merck, speaks at the Reuters Health Summit in New York, in this file image taken November 19, 2008. Merck & Co Inc. said on March 9, 2009 that it would acquire Schering-Plough Corp for $41.1 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks. REUTERS/Brendan McDermid/Files (UNITED STATES BUSINESS HEADSHOT HEALTH SCI TECH) 
SUMMIT-HEALTH/
RTXAGS 
November 13, 2007 
Fred Hassan, CEO of Schering-Plough Corp., speaks at the Reuters Health Summit in New York, November... 
New York, UNITED STATES 
Fred Hassan, CEO of Schering-Plough Corp., speaks at the Reuters Health Summit in New York 
Fred Hassan, CEO of Schering-Plough Corp., speaks at the Reuters Health Summit in New York, November 13, 2007. REUTERS/Brendan McDermid (UNITED STATES) 
SUMMIT-HEALTH/
RTXAGO 
November 13, 2007 
Fred Hassan, CEO of Schering-Plough Corp., speaks at the Reuters Health Summit in New York, November... 
New York, UNITED STATES 
Fred Hassan, CEO of Schering-Plough Corp., speaks at the Reuters Health Summit in New York 
Fred Hassan, CEO of Schering-Plough Corp., speaks at the Reuters Health Summit in New York, November 13, 2007. REUTERS/Brendan McDermid (UNITED STATES) 
SUMMIT-HEALTH/
RTXAGI 
November 13, 2007 
Fred Hassan, CEO of Schering-Plough Corp., speaks at the Reuters Health Summit in New York, November... 
New York, UNITED STATES 
Fred Hassan, CEO of Schering-Plough Corp., speaks at the Reuters Health Summit in New York 
Fred Hassan, CEO of Schering-Plough Corp., speaks at the Reuters Health Summit in New York, November 13, 2007. REUTERS/Brendan McDermid (UNITED STATES) 
HASSAN
RTXMBJU 
November 21, 2003 
Fred Hassan, CEO of Schering-Plough, talks to reporters November 21, 2003 during the Reuters Health Summit... 
New York, USA 
Fred Hassan, CEO of Schering-Plough, talks to reporters November 21, 2003 during the Reuters Health ..... 
Fred Hassan, CEO of Schering-Plough, talks to reporters November 21, 2003 during the Reuters Health Summit in New York City. 
RTRS20N 
November 21, 2003 
Fred Hassan, CEO of Schering-Plough, talks to reporters November 21, 2003
during the Reuters Health... 
UNITED STATES 
SCHERING-PLOUGH CEO FRED HASSAN SPEAKS IN NEW YORK. 
Fred Hassan, CEO of Schering-Plough, talks to reporters November 21, 2003
during the Reuters Health Summit in New York. REUTERS/Jeff Christensen

JC 
RTR7HJ2 
November 21, 2003 
Fred Hassan, CEO of Schering-Plough, talks to reporters November 21, 2003
during the Reuters Health... 
UNITED STATES 
SCHERING-PLOUGH CEO FRED HASSAN SPEAKS IN NEW YORK. 
Fred Hassan, CEO of Schering-Plough, talks to reporters November 21, 2003
during the Reuters Health Summit in New York City. REUTERS/Jeff Christensen

JC 
Sort by 
Display 
Items per page 
Page 
of 1